VANCE: First-in-human phase I study of a novel ChAdOx1-MVA 5T4 vaccine in low and intermediate risk prostate cancer

VANCE: First-in-human phase I study of a novel ChAdOx1-MVA 5T4 vaccine in low and intermediate risk prostate cancer

Detaylı Bibliyografya
Asıl Yazarlar:	Redchenko, I, Cappuccini, F, Pollock, E, Bryant, R, Carter, L, Verrill, C, Hollidge, J, Goodwin, L, Harrop, R, Romero, P, Vigano, S, Evans, T, Catto, J, Hamdy, F, Hill, A
Materyal Türü:	Conference item
Baskı/Yayın Bilgisi:	American Society of Clinical Oncology 2018

Benzer Materyaller

Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control
Yazar:: Wajja, A, ve diğerleri
Baskı/Yayın Bilgisi: (2024)

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
Yazar:: Zhang, C, ve diğerleri
Baskı/Yayın Bilgisi: (2023)

Effect of Prior ChAdOx1 COVID-19 Immunisation on T-Cell Responses to ChAdOx1-HBV
Yazar:: Charlotte Davis, ve diğerleri
Baskı/Yayın Bilgisi: (2024-06-01)

Lyophilization to enable distribution of ChAdOx1 and ChAdOx2 adenovirus-vectored vaccines without refrigeration
Yazar:: Cheng Zhang, ve diğerleri
Baskı/Yayın Bilgisi: (2023-06-01)

Stability of Chimpanzee Adenovirus Vectored Vaccines (ChAdOx1 and ChAdOx2) in Liquid and Lyophilised Formulations
Yazar:: Adam Berg, ve diğerleri
Baskı/Yayın Bilgisi: (2021-10-01)

Impact of ChAdOx1 or DNA Prime Vaccination on Magnitude, Breadth, and Focus of MVA-Boosted Immunogen-Specific T Cell Responses
Yazar:: Alex Olvera, ve diğerleri
Baskı/Yayın Bilgisi: (2024-03-01)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
Yazar:: Hermosilla, E, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

Durability of ChAdOx1 nCov-19 vaccination in people living with HIV
Yazar:: Ogbe, A, ve diğerleri
Baskı/Yayın Bilgisi: (2022)

ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice
Yazar:: Alharbi, N, ve diğerleri
Baskı/Yayın Bilgisi: (2017)

Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2
Yazar:: Eduardo Hermosilla, ve diğerleri
Baskı/Yayın Bilgisi: (2022-03-01)

Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: A phase I clinical trial
Yazar:: Cappuccini, F, ve diğerleri
Baskı/Yayın Bilgisi: (2020)

Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV
Yazar:: Ane Ogbe, ve diğerleri
Baskı/Yayın Bilgisi: (2022-04-01)

Combined intranasal and intramuscular parainfluenza 5-, simian adenovirus ChAdOx1- and poxvirus MVA-vectored vaccines induce synergistically HIV-1-specific T cells in the mucosa
Yazar:: Ashley C. Beavis, ve diğerleri
Baskı/Yayın Bilgisi: (2023-07-01)

Clinical assessment of ChAdOx1 vectored vaccines against emerging pathogens
Yazar:: Moreira Folegatti, P
Baskı/Yayın Bilgisi: (2021)

Population-wide persistent hemostatic changes after vaccination with ChAdOx1-S
Yazar:: Bas de Laat, ve diğerleri
Baskı/Yayın Bilgisi: (2022-07-01)

Thromboses of major arteries and ChAdOx1 nCov-19 vaccination
Yazar:: Rujittika Mungmunpuntipantip, ve diğerleri
Baskı/Yayın Bilgisi: (2021-11-01)

Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination
Yazar:: Simone Barocci, ve diğerleri
Baskı/Yayın Bilgisi: (2022-03-01)

Widespread Arterial Thrombosis after ChAdOx1 nCov-19 Vaccination
Yazar:: Giorgio Berlot, ve diğerleri
Baskı/Yayın Bilgisi: (2022-01-01)

Process- and product-related impurities in the ChAdOx1 nCov-19 vaccine
Yazar:: Lea Krutzke, ve diğerleri
Baskı/Yayın Bilgisi: (2022-07-01)

LGI-1 encephalopathy following ChAdOx1 nCov-19 vaccination
Yazar:: Tamara Garibashvili, ve diğerleri
Baskı/Yayın Bilgisi: (2022-06-01)

Persistent and robust antibody responses to ChAdOx1-S Oxford-AstraZeneca (ChAdOx1-S, Covishield) SARS-CoV-2 vaccine observed in Ugandans across varied baseline immune profiles.
Yazar:: Jennifer Serwanga, ve diğerleri
Baskı/Yayın Bilgisi: (2024-01-01)

Heterologous Combination of ChAdOx1 and MVA Vectors Expressing Protein NS1 as Vaccination Strategy to Induce Durable and Cross-Protective CD8+ T Cell Immunity to Bluetongue Virus
Yazar:: Sergio Utrilla-Trigo, ve diğerleri
Baskı/Yayın Bilgisi: (2020-06-01)

A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime - MVA85A boost in healthy UK adults
Yazar:: Wilkie, M, ve diğerleri
Baskı/Yayın Bilgisi: (2019)

IgA Vasculitis Following ChAdOx1 nCoV-19 Vaccination
Yazar:: Manabendra Basu, ve diğerleri
Baskı/Yayın Bilgisi: (2024-01-01)

DIC-Like Syndrome Following Administration of ChAdOx1 nCov-19 Vaccination
Yazar:: Gerardo Casucci, ve diğerleri
Baskı/Yayın Bilgisi: (2021-06-01)

Impact of Improper Storage of ChAdOx1-S (AstraZeneca) Vaccine on Its Efficacy and Safety
Yazar:: Marek Mikołajczyk, ve diğerleri
Baskı/Yayın Bilgisi: (2022-12-01)

Arterial thrombosis following first-dose ChAdOx1 vaccination: a case series
Yazar:: Christopher Ward, ve diğerleri
Baskı/Yayın Bilgisi: (2022-05-01)

AZD1222 (ChAdOx1 nCoV-19) Vaccine: Hurdles and Visions
Yazar:: Md. Altamash Ahmad, ve diğerleri
Baskı/Yayın Bilgisi: (2023-03-01)

ChAdOx1 vaccination, blood coagulation, and inflammation: No effect on coagulation but increased interleukin‐6
Yazar:: Loes H. Willems, ve diğerleri
Baskı/Yayın Bilgisi: (2021-12-01)

Primary ChAdOx1 vaccination does not reactivate pre-existing, cross-reactive immunity
Yazar:: Larissa Henze, ve diğerleri
Baskı/Yayın Bilgisi: (2023-01-01)

Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia
Yazar:: Salma Al Bahrani, ve diğerleri
Baskı/Yayın Bilgisi: (2021-09-01)

Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial
Yazar:: Zoltán Bánki, ve diğerleri
Baskı/Yayın Bilgisi: (2022-06-01)

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
Yazar:: Pedro M. Folegatti, ve diğerleri
Baskı/Yayın Bilgisi: (2019-05-01)

Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial
Yazar:: Andrew Protheroe, ve diğerleri
Baskı/Yayın Bilgisi: (2020-05-01)

Immune response and safety of heterologous ChAdOx1-nCoV-19/mRNA-1273 vaccination compared with homologous ChAdOx1-nCoV-19 or homologous mRNA-1273 vaccination
Yazar:: Wang-Huei Sheng, ve diğerleri
Baskı/Yayın Bilgisi: (2022-04-01)

Safety and efficacy of ChAdOx1 RVF vaccine against Rift Valley fever in pregnant sheep and goats
Yazar:: Stedman, A, ve diğerleri
Baskı/Yayın Bilgisi: (2019)

ChAdOx1 nCoV-19 vaccine: asymptomatic efficacy estimates - author's reply
Yazar:: Voysey, M, ve diğerleri
Baskı/Yayın Bilgisi: (2021)

Safety and Immunogenicity of a Novel Recombinant Simian Adenovirus ChAdOx2 as a Vectored Vaccine
Yazar:: Folegatti, P, ve diğerleri
Baskı/Yayın Bilgisi: (2019)

Design, Immunogenicity and Preclinical Efficacy of the ChAdOx1.COVconsv12 Pan-Sarbecovirus T-Cell Vaccine
Yazar:: Edmund G.-T. Wee, ve diğerleri
Baskı/Yayın Bilgisi: (2024-08-01)

Impact of ChAdOx1 nCoV-19 (Covishield™) Vaccination: How Long Will It Persist?
Yazar:: Leimapokpam Sumitra Devi, ve diğerleri
Baskı/Yayın Bilgisi: (2022-01-01)